Skip to main content

Table 5 Non-susceptibility rates of the most prevalent non-invasive bacterial pathogens from Gabon

From: Retrospective analysis of antimicrobial resistance and bacterial spectrum of infection in Gabon, Central Africa

Pathogen (n)

Antimicrobial non-susceptibility (%)

PEN/AMPa

COX

AMP + BLI

CRO

GEN

CIP

CHL

CLI

ERY

SXT

TCY

S. aureus (312)

94.2

8.33

8.33

8.33

2.3

9.4

0.9

2.5

17.0

8.3

37.5

S. pyogenes (69)

8.6

-

-

0

-

-

9.1

7.8

7.9

56.0

-

S. pneumoniae (19)

6.7

-

-

ND

-

-

14.3

10.5

11.1

82.4

ND

E. faecalis (19)

0

-

-

-

-

81.3

-

-

-

-

-

K. pneumoniae (56)

100

-

51.9

38.9

38.2

21.4

55.6

-

-

60

ND

P. agglomerans (6)

83.3

-

75.5

ND

0

0

ND

-

-

0

ND

P. aeruginosa (39)

-

-

0b

0c

0d

2.6

-

-

-

-

-

P. mirabilis (52)

34.6

-

17.3

2.1

13.5

1.9

44.4

-

-

48.9

ND

E. coli (114)

80.4

-

60.3

16.4

14.7

24.1

35.5

-

-

88.1

ND

S. enterica (9)

22.2

-

ND

0

0

0

0

-

-

12.5

0

  1. Note: Abbrevations are penicillin/ampicillin (PEN/AMP), cefoxitin (COX), ampicillin plus betalactamase-inhibitor (AMP + BLI), ceftriaxone (CRO), gentamicin (GEN), ciprofloxacin (CIP), chloramphenicol (CHL), clindamycin (CLI), erythromycin (ERY), cotrimoxazole (SXT), tetracycline (TCY), not done (ND). Non-susceptible isolates are shown as the percentage of tested isolates.
  2. aShown is the non-susceptibility of Gram-positives to penicillin and the non-susceptibility of Gram-negatives and E. faecalis to ampicillin.
  3. bNon-susceptibility to piperacillin/tazobactam.
  4. cNon-susceptibility to ceftazidim.
  5. dNon-susceptibility to amikacin.
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us